Abstract: Methods are provided for close-range intraoperative, endoscopic and intravascular detection and treatment of lesions, including tumors and non-malignant lesions. The methods use antibody fragments or subfragments labeled with isotopic and non-isotopic agents. Also provided are methods for detection and treatment of lesions with photodynamic agents and methods of treating lesions with a protein conjugated to an agent capable of being activated to emit Auger electron or other ionizing radiation. Compositions and kits useful in the above methods are also provided.

Abstract: The present invention relates to an enzyme-antibody complex where one or more molecule(s) of enzyme into which a maleimide group or a thiol group is introduced is/are covalently conjugated to a carrier (polylysine, aminodextyan and so forth) in which a thiol group when a maleimide group is introduced into the enzyme or to a maleimide group when a thiol group is introduced into the enzyme via them, and a maleimide group is introduced into at least one amino group remaining in the above complex and is covalently conjugated to a maleimide group of the above complex via a thiol group obtained by reduction of antibody fragment or antibody. The resulting complex is useful as an enzyme-labeled antibody particularly in immunohistochemistry and in enzyme immunoassay and makes an immunoassay with high sensitivity possible.

Abstract: A method of affinity cross-linking a peptide to an antibody by photo-chemically activating an azido compound in a peptide including said azido compound; adding an antibody to the photochemically activated peptide; and allowing the photochemically activated peptide and the antibody to react. The azido compound has an affinity for a hydrophobic structure in the variable domain of the antibody which binds to nucleotides or nucleosides, binding the peptide into a native binding pocket of the immunoglobulin (Ig) structure of an antibody. The site of cross-linking is located away from the antigen binding site in the Fv domain avoiding the compromise of antigen recognition. A composition of a peptide cross-linked to an antibody is also disclosed.

Abstract: The present invention describes a site specific conjugation method for glycoproteins wherein a stable dihydrazone bond is formed between the glycoproteins and the glycoproteins retain full activity. Also described is a novel glycoprotein-glycoprotein conjugate of the formula wherein X and Y are glycoproteins modified such that the vicinal hydroxyl groups of the carbohydrate moieties in the glycoproteins have been oxidized to aldehydes which are then reacted with a hydrazide functional group to form a hydrazone bond which is represented in Formula I by “—C═NNH—”.

Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed.

Abstract: Bifunctional aromatic compounds which are capable of linking metal ions to biologically useful molecules. The bifunctional compounds are characterized as having a hydrazine or hydrazide group and a protein reactive group. The hydrazine or hydrazide group may be protected as a lower alkyl hydrazone. Conjugates of the bifunctional compounds with macromolecules are also described and labelled macromolecules comprised of the conjugates and metal ions are provided. Additionally, a method is provided for forming a labelled macromolecule by reacting a conjugate with a metal species. The compounds and method of this invention are particularly useful in the fields of biology and medicine for imaging and/or therapy.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

Abstract: A method of labelling a protein with a metal involving chelating a metal to a compound, with a molecular weight of at least 1,000, and a reactive group capable of forming a covalent bond with a target protein, and conjugating the metallically-labelled compound to a protein.

Abstract: The invention pertains to an electrically conductive copolymer of the general formula I: wherein A is a first polymerizable monomer which produces an electrically conductive polymer when polymerized, and represents a polymerized unit of said monomer A in the electrically conductive polymer; B is a second polymerizable monomer which when copolymerized with monomer A produces an electrically conductive polymer, and represents a polymerized unit of said monomer B in the electrically conductive polymer; w is an integer greater than or equal to 0; x is an integer greater than or equal to 1; y is an integer greater than or equal to 0; z is an integer greater than or equal to I; 11, and 12 are each independently covalent linkers or spacer arms; 13 is substituent group having a desired chemical functionality; and Bt′ is selected from the group consisting of biotin and complexes of biotin with a molecule selected from the group consisting of avidin, streptavidin, derivatives of avidin

Abstract: The present invention relates to stable compositions useful as primary standards and calibrators and controls comprising a cardiac troponin I (cTnI) such as native, recombinant, addition and deletion forms thereof, whether or not complexed with other troponin subunits such as TnC and/or TnT, in an inactivated human serum. The compositions are obtained by incubating troponin complexes with human serum. The compositions are characterized by an immunodetectability ratio of epitopes on the N-terminal segment to epitopes on the C-terminal segment substantially equivalent to that of pooled, fresh serum from acute myocardial infarction patients.